- Home
- TLSA vs GNTA Comparison
TLSA vs GNTA Comparison
Compare TLSA & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- GNTA
- Stock Information
- Founded
- TLSA 2013
- GNTA 2014
- Country
- TLSA United Kingdom
- GNTA Italy
- Employees
- TLSA N/A
- GNTA N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLSA Health Care
- GNTA Health Care
- Exchange
- TLSA Nasdaq
- GNTA Nasdaq
- Market Cap
- TLSA 187.0M
- GNTA 62.9M
- IPO Year
- TLSA 2000
- GNTA 2021
- Fundamental
- Price
- TLSA $1.66
- GNTA $3.10
- Analyst Decision
- TLSA
- GNTA Strong Buy
- Analyst Count
- TLSA 0
- GNTA 1
- Target Price
- TLSA N/A
- GNTA $25.00
- AVG Volume (30 Days)
- TLSA 325.5K
- GNTA 16.3K
- Earning Date
- TLSA 05-06-2025
- GNTA 01-01-0001
- Dividend Yield
- TLSA N/A
- GNTA N/A
- EPS Growth
- TLSA N/A
- GNTA N/A
- EPS
- TLSA N/A
- GNTA N/A
- Revenue
- TLSA N/A
- GNTA N/A
- Revenue This Year
- TLSA N/A
- GNTA N/A
- Revenue Next Year
- TLSA N/A
- GNTA N/A
- P/E Ratio
- TLSA N/A
- GNTA N/A
- Revenue Growth
- TLSA N/A
- GNTA N/A
- 52 Week Low
- TLSA $0.63
- GNTA $2.56
- 52 Week High
- TLSA $2.60
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- TLSA 43.10
- GNTA 40.06
- Support Level
- TLSA $1.63
- GNTA $2.56
- Resistance Level
- TLSA $1.88
- GNTA $3.18
- Average True Range (ATR)
- TLSA 0.15
- GNTA 0.25
- MACD
- TLSA -0.01
- GNTA -0.05
- Stochastic Oscillator
- TLSA 38.46
- GNTA 32.93
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.